Sanders: Novo won’t be penalized for cutting Ozempic prices, STATNews reports

Senator Bernie Sanders said during a Senate health committee hearing on Tuesday that major drug middlemen have agreed not to limit coverage of Novo Nordisk’s (NVO) Ozempic and Wegovy if the company lowers the prices of the treatments, STATNews’ Rachel Cohrs Zhang and Elaine Chen reports. Sanders said Cigna (CI), CVS (CVS) and UnitedHealth (UNH) will still cover cheaper versions of Ozempic if Novo Nordisk “were to substantially reduce the list price for Ozempic and Wegovy.” Sanders said that all of the major PBMs said that they would expand coverage for these drugs if the list price was reduced.